Tandem Diabetes Care, Inc. (TNDM)
| Market Cap | 966.95M -16.7% |
| Revenue (ttm) | 1.03B +4.5% |
| Net Income | -94.55M |
| EPS | -1.39 |
| Shares Out | 68.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,640,166 |
| Open | 14.41 |
| Previous Close | 14.69 |
| Day's Range | 13.95 - 14.83 |
| 52-Week Range | 9.98 - 29.65 |
| Beta | 1.64 |
| Analysts | Buy |
| Price Target | 27.79 (+96.95%) |
| Earnings Date | May 7, 2026 |
About TNDM
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a pe... [Read more]
Financial Performance
In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price target is $27.79, which is an increase of 96.95% from the latest price.
News
Tandem Diabetes Care Transcript: Bank of America Global Healthcare Conference 2026
Record Q1 results were achieved amid major business model changes, including the PayGo pharmacy launch and direct international sales. Pharmacy channel coverage is expanding, new product launches like Mobi are set to drive growth, and profitability is improving with strong customer retention.
Tandem Diabetes initiated with a Hold at Benchmark
Benchmark analyst Bruce Jackson last night initiated coverage of Tandem Diabetes (TNDM) with a Hold rating and no price target The company is undertaking an “ambitious strategy” to simultaneously shif...
Tandem Diabetes initiated with a Hold at Benchmark
Benchmark initiated coverage of Tandem Diabetes (TNDM) with a Hold rating.
Tandem Diabetes price target lowered to $55 from $56 at Barclays
Barclays lowered the firm’s price target on Tandem Diabetes (TNDM) to $55 from $56 and keeps an Overweight rating on the shares.
Tandem Diabetes price target raised to $24 from $22 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Tandem Diabetes (TNDM) to $24 from $22 and keeps a Neutral rating on the shares.
Tandem Diabetes Care Earnings Call Transcript: Q1 2026
Record Q1 pump shipments and sales, margin expansion, and strong cash flow marked the quarter. Key launches and direct international expansion support reaffirmed 2026 guidance, despite ongoing infusion set supply challenges.
Tandem Diabetes Care Announces First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2...
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the ...
Tandem announces U.S. FDA cleared Control-IQ+ AID tech for use in pregnancy
Tandem Diabetes (TNDM) Care announced that the United States Food and Drug Administration, FDA, has cleared Control-IQ+ automated insulin delivery, AID, technology for use in pregnancy complicated by ...
Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type 1 diabetes.
Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Issie Kirby raised the firm’s price target on Tandem Diabetes (TNDM) to $45 from $36 and keeps a Buy rating on the shares, offering over…
Tandem Diabetes price target raised to $28 from $25 at TD Cowen
TD Cowen raised the firm’s price target on Tandem Diabetes (TNDM) to $28 from $25 and keeps a Buy rating on the shares. The firm updated its model to map…
Tandem Diabetes price target raised to $28 from $25 at TD Cowen
TD Cowen raised the firm’s price target on Tandem Diabetes (TNDM) to $28 from $25 and keeps a Buy rating on the shares. The firm updated its model to map…
Citi adds ‘upside 90-day catalyst watch’ on Tandem Diabetes
Citi analyst Joanne Wuensch added an “upside 90-day catalyst watch” on Tandem Diabetes (TNDM) while keeping a Neutral rating on the shares with a $22 price target The firm believes…
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial m...
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. , (“ Tandem " or the "Company") ( NASDAQ:TNDM) investors that the firm has initiated an investi...
Truist upgrades Tandem Diabetes to Buy on growing conviction in upside potential
As previously reported, Truist analyst Richard Newitter upgraded Tandem Diabetes (TNDM) to Buy from Hold with a price target of $35, up from $27. The firm is citing its growing…
Tandem Diabetes upgraded to Buy from Hold at Truist
Truist upgraded Tandem Diabetes (TNDM) to Buy from Hold with a price target of $35, up from $27. The firm notes that the company’s pharmacy shift is accelerating its revenue…
Tandem Diabetes Care Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Management outlined rapid progress in shifting to the pharmacy channel, driving record gross margins and projecting further gains as pharmacy sales grow. Product launches, including Mobi tubeless and Sigi, will address both tubed and tubeless market segments, while international expansion and technology integration remain key priorities.
Tandem Diabetes upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Matt O’Brien upgraded Tandem Diabetes (TNDM) to Overweight from Neutral with a price target of $33, up from $21. Piper upgrades the shares following an analysis of…
Tandem Mobi Now Compatible with Android Smartphones
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smalle...
Tandem Diabetes Care Transcript: TD Cowen 46th Annual Health Care Conference
The business is undergoing a strategic transformation with a shift to a PAYGO model, expanded pharmacy access, and a robust innovation pipeline including Mobi Tubeless and a fully closed loop algorithm. These initiatives are expected to drive double-digit growth, higher margins, and improved patient access.
Tandem Diabetes Care Transcript: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day
Record Q4 performance was driven by commercial transformation, new product launches, and a strategic shift to the pharmacy channel. The transition to direct sales internationally and a pay-as-you-go model in the U.S. is expected to drive recurring revenue and margin expansion, with significant growth projected for 2027.
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amou...
Tandem Diabetes price target raised to $35 from $30 at BofA
BofA raised the firm’s price target on Tandem Diabetes (TNDM) to $35 from $30 and keeps a Neutral rating on the shares. The firm, which rebuilt its revenue model to…